Raltegravir
- Generic Name
- Raltegravir
- Brand Names
- Isentress
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN6O5
- CAS Number
- 518048-05-0
- Unique Ingredient Identifier
- 22VKV8053U
- Background
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
- Indication
For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Post-exposure prophylaxis for occupational exposure to HIV therapy
A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)Drug: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableOther: SOC adherence versus SOC+CPI adherence
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 545
- Registration Number
- NCT01641367
- Locations
- 🇧🇷
Hospital Nossa Senhora da Conceicao CRS (12201), Porto Alegre, RS, Brazil
🇧🇷Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇮🇳Chennai Antiviral Research and Treatment (CART) CRS (11701), Chennai, Taramani, India
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT01622673
Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load
- Conditions
- Human T-cell Leukemia Virus Type 1 Infection
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT01620736
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Westat
- Target Recruit Count
- 408
- Registration Number
- NCT01618305
- Locations
- 🇹🇭
Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand
🇹🇭Bhumibol Adulyadej Hospital, Bangkok, Thailand
🇧🇷Hospital Nossa Senhora da Conceicao NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
- Conditions
- HIV InfectionTuberculosis
- Interventions
- Drug: Standard-dose Lopinavir/RitonavirDrug: Double-dose Lopinavir/Ritonavir
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 71
- Registration Number
- NCT01601626
- Locations
- 🇵🇪
Asociacion Civil Impacta Salud y Educacion - Miraf CRS (11301), Lima, Peru
🇧🇷Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇭🇹Les Centres GHESKIO CRS (30022), Port-au-Prince, Haiti
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
- Conditions
- HIV Infection
- Interventions
- Drug: Tenofovir, Emtricitabine, Lopinavir/r
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 240
- Registration Number
- NCT01576731
- Locations
- 🇪🇸
Hospital Clínic of Barcelona, Barcelona, Spain
A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01531647
Bone and Body Comp: A Sub Study of the SECOND-LINE Study
- Conditions
- HIV
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 210
- Registration Number
- NCT01513122
- Locations
- 🇿🇦
Desmond Tutu HIV Foundation, Cape Town, South Africa
🇦🇷CEADI, Buenos Aires, Argentina
🇹🇭HIV-NAT Program on AIDS - Thai Red Cross, Bangkok, Thailand
Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- IrsiCaixa
- Target Recruit Count
- 41
- Registration Number
- NCT01480713
- Locations
- 🇪🇸
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
RAltegravir Switch STudy: Effects on Endothelial Recovery
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 24
- Registration Number
- NCT01453933
- Locations
- 🇳🇱
Onze Lieve Vrouwe Gasthuis, Amsterdam, Noord Holland, Netherlands
🇳🇱University Medical Center Utrecht, Utrecht, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.